FDA Greenlights Alzheimer’s Blood Tests

For the first time, simple blood tests and new drugs are changing how doctors find and treat Alzheimer’s disease.

Story Highlights

The Food and Drug Administration (FDA) cleared the first blood tests to help diagnose Alzheimer’s in symptomatic adults.
FDA approved two disease-modifying drugs, Leqembi and Kisunla, for adults with Alzheimer’s.
A new FDA-approved brain scan agent helps doctors see harmful tau protein in living patients.
Experts say these tools improve care now, but they are not a cure and benefits remain modest.

What Changed: First Blood Tests Gain FDA Clearance

In 2025, the Food and Drug Administration cleared the first blood-based test to help diagnose Alzheimer’s in adults 55 and older with symptoms. The test measures proteins linked to the disease and gives doctors a less invasive option than spinal taps or expensive scans. In 2026, the Food and Drug Administration cleared another blood test, PrecivityAD2, for adults 40 and older with signs of cognitive problems. The Alzheimer’s Association highlighted how it can aid diagnosis in real-world clinics.

Hospitals and clinics now have multiple blood tests, with some used to rule out Alzheimer’s before a specialist visit, and others used to support a likely diagnosis. Coverage and care pathways are still forming, but early studies show that using a blood test can improve diagnostic accuracy in primary care and specialty settings. News reports note that four Alzheimer’s blood tests have been cleared in less than two years, signaling fast progress in access.

Treatments Advance: Two Drugs Receive FDA Approval

The Food and Drug Administration gave traditional approval to Leqembi, a drug that targets amyloid, after a confirmatory trial verified clinical benefit. The Food and Drug Administration also approved Kisunla for treatment of adults with Alzheimer’s disease. These drugs aim to slow decline in early disease. Doctors use biomarker tests to identify patients with amyloid, since that is needed to receive these medicines safely and effectively under current labels and guidelines.

These treatments are not a cure. Independent reviews describe benefits as modest for many patients, which matters for families weighing risks, costs, and clinic demands. Still, approval means doctors have options where none existed a few years ago. Better diagnosis can guide who should try these drugs, when to stop, and how to monitor side effects. The growing toolkit pairs detection with therapy, which can help patients plan care earlier in the disease.

Imaging Tools: Seeing Tau Pathology in Living Patients

The Food and Drug Administration approved Tauklarify, a tracer used in brain scans to detect tau protein in adults with cognitive impairment being checked for Alzheimer’s. Tau buildup tracks with brain damage and symptoms. Doctors can now use this scan to identify patients whose decline likely ties to Alzheimer’s, and to support treatment choices and trial enrollment. This complements amyloid tests and blood biomarkers, giving teams a fuller picture of the disease process in each patient.

The National Institutes of Health reported steady progress in tools to detect, diagnose, and track dementia, including advances in biomarkers and data methods. Researchers and clinicians are building clear practice rules for when and how to use blood tests in memory clinics and primary care. As coverage expands and workflows mature, more patients may get answers sooner, without long waits for specialized centers. That can reduce stress on families and cut costs tied to late or wrong diagnoses.

Why This Matters Across the Aisle

Families have long faced a slow, costly, and confusing path to an Alzheimer’s diagnosis. Blood tests and targeted scans can speed answers and match patients to treatments. That is a win for patient choice and transparency. It also pressures insurers and government programs to cover useful tests and drugs without waste. Clear rules, fair pricing, and strong safety checks can protect patients and taxpayers alike, while keeping power in the hands of families and their doctors.

What To Watch Next: Access, Accuracy, and Real-World Impact

Policymakers and health systems will decide how widely these tests and treatments are used. Doctors will refine when to order which test, and how to combine blood tests with scans. Researchers will track real-world outcomes to see who benefits most, and how to reduce risks. If access spreads beyond elite centers, ordinary patients could see faster answers and better planning. The goal now is simple: turn laboratory gains into everyday care that helps people live better, longer.